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Summary
Background The National Health Service (NHS) cancer plan for England was published in 2000, with the aim of 
improving the survival of patients with cancer. By contrast, a formal cancer strategy was not implemented in Wales 
until late 2006. National data on cancer patient survival in England and Wales up to 2007 thus oﬀ er the opportunity 
for a ﬁ rst formal assessment of the cancer plan in England, by comparing survival trends in England with those in 
Wales before, during, and after the implementation of the plan.
Methods We analysed population-based survival in 2·2 million adults diagnosed with one of 21 common cancers 
in England and Wales during 1996–2006 and followed up to Dec 31, 2007. We deﬁ ned three calendar periods: 
1996–2000 (before the cancer plan), 2001–03 (initialisation), and 2004–06 (implementation). We estimated year-on-
year trends in 1-year relative survival for patients diagnosed during each period, and changes in those trends 
between successive periods in England and separately in Wales. Changes between successive periods in mean 
survival up to 5 years after diagnosis were analysed by country and by government oﬃ  ce region of England. Life 
tables for single year of age, sex, calendar year, deprivation category, and government oﬃ  ce region were used to 
control for background mortality in all analyses.
Findings 1-year survival in England and Wales improved for most cancers in men and women diagnosed during 
1996–2006 and followed until 2007, although not all trends were signiﬁ cant. Annual trends were generally higher 
in Wales than in England during 1996–2000 and 2001–03, but higher in England than in Wales during 2004–06. 
1-year survival for patients diagnosed in 2006 was over 60% for 12 of 17 cancers in men and 13 of 18 cancers in 
women. Diﬀ erences in 3-year survival trends between England and Wales were less marked than the diﬀ erences in 
1-year survival. North–South diﬀ erences in survival trends for the four most common cancers were not striking, 
but the North West region and Wales showed the smallest improvements during 2001–03 and 2004–06.
Interpretation The ﬁ ndings indicate slightly faster improvement in 1-year survival in England than in Wales during 
2004–06, whereas the opposite was true during 2001–03. This reversal of survival trends in 2001–03 and 2004–06 
between England and Wales is much less obvious for 3-year survival. These diﬀ erent patterns of survival suggest 
some beneﬁ cial eﬀ ect of the NHS cancer plan for England, although the data do not so far provide a deﬁ nitive 
assessment of the eﬀ ectiveness of the plan.
Funding Oﬃ  ce for National Statistics (contract NT-04/2355A); Cancer Research UK (programme grant C1336/A5735).
Introduction
In 1995, the Expert Advisory Group on Cancer published 
the Calman-Hine report,1 in which they recommended 
that strategic improvements be made to cancer services 
in England and Wales. However, no additional resources 
were provided for the recommended improvements, 
and implementation of the recommendations was left 
to local initiative. By 1999, progress in improving cancer 
services was seen as inadequate.2
The National Health Service (NHS) cancer plan for 
England was published in late 2000.3 It was a 
comprehensive 10-year strategy, designed to improve 
prevention, early diagnosis, and screening, and to 
provide optimal treatment for all patients, thus 
improving survival and quality of life. An important 
feature was the creation of multi-disciplinary teams 
(MDTs) of specialists to oversee the care of each patient. 
Annual funding for cancer services rose by about 35% 
in real terms over the three ﬁ nancial years from 2001 to 
2004.
In Wales, the Cancer Services Expert Group 
recommended substantial changes to cancer services in 
1996.4 Changes included the creation of MDTs and the 
designation of specialist clinicians, but the approach 
relied heavily on clinical collaboration, supported by 
directives from the devolved administration, rather 
than on a formal strategy. The full national cancer plan 
for Wales, Designed to Tackle Cancer,5 was not published 
until late 2006.
3-year progress reports on the NHS cancer plan were 
published in October, 2003,6,7 when, despite substantial 
progress, it was acknowledged that it would take time 
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before the eﬀ ects of the plan could be assessed. Here, 
we have chosen to examine survival trends during two 
3-year periods after the introduction of the plan: 
2001–03 and 2004–06. Population-based cancer survival 
serves as a broad measure of the overall eﬀ ectiveness of 
health services. Survival is generally improving, so to 
measure the eﬀ ect of the NHS cancer plan we looked 
for evidence of any acceleration in survival trends. 
Given the diﬃ  culty of introducing systematic, 
nationwide changes in the NHS, it would be surprising 
if survival trends for patients diagnosed in England 
during 2001–03 were to diﬀ er much from earlier trends 
as a direct result of the plan. However, for patients 
diagnosed during 2004–06, at least 3 years after 
implementation of the plan, any marked improvements 
in the overall eﬀ ectiveness of cancer services might 
reasonably be expected to show an eﬀ ect on trends in 
short-term survival.
Given the later implementation of a strategic cancer 
plan in Wales, comparison of survival trends in England 
and Wales over the same calendar periods could be 
instructive. A cancer plan that was implemented 
nationwide cannot later be assessed in the same way as 
a randomised trial. But an observational comparison of 
outcomes before and after the introduction of a plan in 
one of two adjacent countries, with similar societies 
and health systems, seemed to be a reasonable 
alternative. Similar trends in cancer survival might be 
expected in both countries up to 2000. But, if the cancer 
plan were eﬀ ective, we would expect that England 
would experience a faster improvement in survival 
than Wales after several years of latency. Up to 7 years 
of follow-up are available for patients diagnosed since 
the introduction of the plan. 1-year survival trends 
might be expected to accelerate more rapidly in 
successive calendar periods in England than in Wales 
after the introduction of the plan, if the plan was 
eﬀ ective. 3-year survival trends might also be diﬀ erent 
in England and Wales.
On Dec 10, 2008, the Oﬃ  ce for National Statistics 
(ONS) published the oﬃ  cial national statistics on 
survival for patients diagnosed with one of 21 common 
cancers in England during 2000–04 and followed up to 
2005.8 National statistics on survival for cancer patients 
diagnosed in England during 2001–06 and followed up 
to Dec 31, 2007, were published on March 20, 2009.9 We 
have used these data, and the data for all cancer patients 
diagnosed in Wales, to study national and regional 
trends in survival up to the end of 2007.
Methods
Data collection
Population-based cancer registries collect a small 
standard dataset for all cancer patients in a deﬁ ned 
population. Data-collection methods vary between 
cancer registries, but the main sources of data are 
hospital in-patient records and pathology records. The 
National Cancer Registry has collated data from regional 
cancer registries covering the entire population of 
England and Wales since 1962. Since 1971, the National 
Health Service Central Register (NHSCR) has provided 
notiﬁ cation of the deaths of all cancer patients whose 
record was successfully ﬂ agged with details of the initial 
cancer registration.
Data for this study were extracted from the National 
Cancer Registry at the ONS after the linkage of cancer 
records with data on the patient’s vital status (alive, 
emigrated, dead, not traced) at NHSCR. After powers to 
legislate on health policy were devolved to UK national 
assemblies from 1997, cancer registration in Wales 
passed to the Welsh Cancer Intelligence and Surveillance 
Unit, but the National Cancer Registry at the ONS 
continues to receive cancer data from Wales, and the 
vital status of all cancer patients in England and Wales 
is updated by the ONS. When the data were extracted 
on Oct 17, 2008, the vital status at Dec 31, 2007, was 
known for 99·6% of patients diagnosed with cancer 
during 1996–2006, without regional variation. The data 
were received on Dec 15, 2008.
Cancers were deﬁ ned by their anatomical location 
(site), morphology, and behaviour (benign, in situ, or 
invasive). Tumour site was coded according to the tenth 
revision of the International Classiﬁ cation of Diseases 
(ICD-10).10 Morphology and behaviour were coded 
according to the second edition of the International 
Classiﬁ cation of Diseases for Oncology (ICD-O-2).11 We 
examined data for 21 common cancers, 17 in men and 
18 in women. We analysed survival for laryngeal cancer 
in men only, and for breast cancer in women only. Data 
on stage at diagnosis were not available for all patients 
and could not be usefully incorporated in our analyses. 
Standard criteria were used to decide whether a tumour 
record was eligible for inclusion in the analyses.12 
Records were excluded if they contained data of 
inadequate quality or were for patients not resident in 
England or Wales. 1·25 million of 8·4 million patients 
registered with benign tumours (behaviour code 0), 
tumours of uncertain behaviour (code 1), in-situ 
neoplasms (code 2) or a metastasis (code 6) were not 
included. Of 7 043 765 patients with an invasive primary 
malignancy eligible for survival analysis during 
1971–2006, 6 436 299 (91·4%) had one of the 21 cancers 
selected for analysis, of whom 2 338 785 were diagnosed 
during 1996–2006. 6·2% of patients were excluded 
because their survival was either zero or unknown 
(tumour registered from a death certiﬁ cate only [DCO]), 
and 1·4% of patients were excluded because of unknown 
vital status or sex, duplicate registration, synchronous 
tumours, or invalid dates or sequences of dates. Patients 
who had had a previous cancer of the same organ or 
tissue at any time since 1971 were also excluded. Data 
were analysed for 2 163 274 adults diagnosed with a 
primary malignant neoplasm during 1996–2006: 92·5% 
of those eligible (table 1). 
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The government oﬃ  ce regions of England have 
provided a geographic focus for public-health policy in 
England since 1999, and have been closely linked with 
the new NHS strategic health authorities since 2006.13 
We analysed the cancer data for each region, for England 
as a whole, and separately for Wales.
Statistical analysis
Survival trends were quantiﬁ ed as the year-on-year rate 
of change within each calendar period. The diﬀ erence 
in survival trends between successive calendar periods 
provides a measure of any acceleration (or deceleration) 
in the rate of change in survival between successive 
periods. Diﬀ erences or trends are given as the simple 
arithmetic values; so 12% is reported as 2% (not 20%) 
higher than 10%, and a rise from 10% to 14% over 
4 years is reported as an increase of 1% per year.
We estimated relative survival for England, for Wales, 
and for the nine government oﬃ  ce regions of England, 
for each cancer, each sex, and by year or period of 
diagnosis. Relative survival is the ratio of the observed 
probability of survival and the probability that would 
have been expected if the cancer patients had only 
experienced the normal (background) mortality of the 
general population in which they live,14,15 given the same 
distribution of factors such as age, sex, geographic area, 
calendar period, and deprivation. Relative survival is 
the standard approach to estimating population-based 
survival. It does not rely on accurate reporting of the 
cause of death,16 and it enables the estimation of long-
term survival from cancer, when competing causes of 
death become more important.17 It can be interpreted as 
survival from cancer after adjustment for other causes 
of death.
Expected survival is derived from population life 
tables. Background mortality rates by age and sex diﬀ er 
widely between socioeconomic groups and geographic 
regions in England and Wales,18 and these diﬀ erences 
have changed over time. We therefore constructed life 
tables (available online19) of all-cause death rates by 
single year of age (0–99 years), sex, deprivation category, 
and government oﬃ  ce region for 1991, 2001, and 2005, 
using the mid-year population estimates and the mean 
annual number of deaths during the 3 years centred on 
the index year. Linear interpolation was then used to 
obtain life tables for each calendar year in the period 
1992–2005. Life tables for 2006 and 2007 could not be 
constructed because the relevant data (deaths during 
2007–08) were unavailable, so life tables for 2005 were 
used for those years without extrapolation. National 
and regional analyses for England were all done with 
life tables speciﬁ c for sex, government oﬃ  ce region, 
deprivation category, and calendar year from 1996.
Five deprivation categories were deﬁ ned from 
quintiles of the income domain score of the indices of 
multiple deprivation (IMD2004),20 and the equivalent 
indices for Wales,21 using administrative data for the 
34 378 lower super-output areas (LSOAs, mean 
population 1500)22 in England (2001) and Wales 
(2002–04). Cancer patients were assigned to the 
deprivation category of their LSOA, using the postcode 
of residence at diagnosis and a combined historic ﬁ le of 
2·1 million unique full postcodes, each linked to a 
complete set of geographic area codes for each year that 
the postcode was active. Death records were assigned to 
deprivation categories using the postcode and LSOA in 
the same way as the cancer cases, so that background 
mortality was precisely matched to the small areas of 
residence and deprivation categories of the cancer 
patients. Although socioeconomic inequalities (the so-
called deprivation gap) in survival have been widening 
for many adult cancers in England and Wales,23 tending 
to reduce the overall national gain in survival, recent 
trends in the deprivation gap in survival will be reported 
separately.
Survival probabilities were estimated at short (for 
example, 1-month) intervals in the ﬁ rst few months 
ICD-10* code Eligible for 
analysis
Exclusions (%) Number of patients 
included (%)
DCO† Zero survival‡ Other§
Oesophagus C15 71 205 3·8 1·9 0·5 66 829 (93·9)
Stomach C16 88 637 4·6 2·9 0·5 81 517 (92·0)
Colon C18 213 077 4·3 2·6 1·5 195 108 (91·6)
Rectum C19–C21 125 458 2·3 1·4 0·6 120 023 (95·7)
Pancreas C25 70 897 10·6 5·4 0·4 59 272 (83·6)
Larynx (men) C32 17 281 2·0 1·0 0·8 16 624 (96·2)
Lung C33, C34 366 597 6·9 4·2 0·7 323 157 (88·2)
Melanoma C43 74 004 0·9 0·3 1·5 71 935 (97·2)
Breast (women) C50 411 299 2·1 0·9 3·5 384 442 (93·5)
Cervix C53 29 077 1·7 0·9 1·2 27 998 (96·3)
Uterus C54, C55 59 567 2·1 1·1 0·6 57 306 (96·2)
Ovary C56, 57·0–57·7 66 383 4·5 2·4 0·7 61 385 (92·5)
Prostate C61 300 301 3·2 1·2 0·9 284 310 (94·7)
Testis C62 18 679 0·4 0·2 2·1 18 194 (97·4)
Kidney C64–C66, C68 63 650 5·5 3·2 0·9 57 536 (90·4)
Bladder C67 112 712 2·7 1·2 0·8 107 398 (95·3)
Brain C71 39 220 4·7 2·1 1·0 36 171 (92·2)
Hodgkin’s 
disease
C81 13 655 0·8 0·6 1·2 13 305 (97·4)
Non-Hodgkin 
lymphoma
C82–C85 93 186 3·0 2·2 1·2 87 207 (93·6)
Myeloma C90 36 866 5·0 2·5 0·7 33 865 (91·9)
Leukaemia C91–C95 67 034 6·9 3·3 0·8 59 692 (89·0)
Total 2 338 785 4·0 2·2 1·4 2 163 274 (92·5)
All patients were aged 15–99 years. *Tenth revision of the International Classiﬁ cation of Diseases. †Registration 
from a death certiﬁ cate only (DCO). ‡Date of diagnosis same as date of death, but record not ﬂ agged as a DCO 
registration. §Aged 100 years or over at diagnosis, vital status or sex unknown, sex-site error, invalid dates, 
duplicate registration, synchronous tumours, or a previous cancer of the same organ or tissue at some time 
since 1971.
Table 1: Number of patients eligible and included for analysis, and percentage exclusions, for adults 
diagnosed with one of 21 common cancers in England and Wales between 1996–2006 and followed up 
to 2007
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after diagnosis, then at progressively longer intervals 
up to 10 years after diagnosis, using the maximum-
likelihood approach for individual data.24 We report the 
cumulative probabilities of relative survival at 1, 3, 5, 
and 10 years after diagnosis. We also report 5-year 
survival for patients who survived at least 1 year after 
their diagnosis (conditional survival).
Given the structure of the data, various analytical 
approaches were required. The classical (cohort) approach 
was suitable for the analysis of year-on-year trends in 
1-year survival, since all patients were followed up at least 
that long (ﬁ gure 1). For the period 1996–2000, the cohort 
approach was used for 5-year survival and the complete 
approach to estimate 10-year survival. Short-term 
prediction of survival for patients diagnosed during 2007 
was made with the hybrid approach,25 combining the 
1-year survival probability for patients diagnosed during 
2006 with the survival probabilities for the second and 
later years after diagnosis for patients who were alive and 
followed up for at least part of 2007. Conditional 5-year 
survival was available with the cohort approach for 
1996–2000, the complete approach for 2001–03, and the 
period approach26 for 2004–06 (ﬁ gure 1).
Year-on-year trends in survival were estimated within 
a single variance-weighted linear regression27 model 
covering all 11 years and each calendar period, including 
two extra parameters in addition to the baseline trend, 
to allow for diﬀ erent trends in successive periods. We 
report the relative survival estimate derived from the 
regression model for the last year of each calendar 
period. We report changing survival trends as the 
absolute diﬀ erence between the regression slopes for 
each calendar period: a positive value implies 
acceleration of the upward trend in survival and a 
negative value implies deceleration (see webappendix). 
Survival analyses were done with the publicly available 
Stata program strel.28 Other analyses were programmed 
in Stata version 10.29
We constructed funnel plots30 to visualise the regional 
variability of 1-year survival in England and Wales for 
cancer patients diagnosed during 2004–06. The plots 
allowed us to estimate how much a particular estimate of 
survival deviates from the pooled England value (the 
target), given the precision of each estimate. 1-year 
relative survival estimates for 2004–06 for each population 
were plotted against the precision of the estimates, taken 
as the inverse square of their standard errors. The target 
value, taken as the estimate of 1-year relative survival 
pooled across the nine regions of England for all patients 
diagnosed during 2004–06, is represented by the 
horizontal line in each plot. Wales was not included in 
the target value, so that the estimates for Wales could be 
compared with those for England. The 95% and 99·8% 
control limits, derived from the complementary log–log 
transformation of the target estimate for England across 
the observed range of precision of the regional estimates,31 
represent approximately two and three standard 
deviations, respectively, from the target value at each level 
of precision (webappendix). Estimates that lie inside the 
control limits were considered as within the geographical 
variation that could be expected by chance.
Funnel plots were also constructed to show regional 
variation in the year-on-year trend in 1-year survival 
during 2004–06. The target value in each plot was set as 
the mean absolute change per year between the 1-year 
relative survival estimates for all patients in England 
diagnosed in the single years 2004, 2005, and 2006. The 
control limits were constructed on the assumption that 
the target value for the year-on-year change in survival 
follows a normal distribution (see webappendix).
This analytical strategy, including deﬁ nition of the 
calendar periods, the cancers, life tables, approaches to 
estimation of survival and survival trends, and the 
structure of the tables and graphics, was speciﬁ ed in 
advance, after data preparation was complete but before 
the start of any analyses. This was done to pre-empt any 
concerns regarding possible data-dredging in favour of 
a particular conclusion, whether for or against the 
eﬀ ectiveness of the NHS cancer plan.
Legal authority to hold the cancer data derives from a 
contract with the ONS to produce the oﬃ  cial national 
statistics32 on cancer survival. Approval to analyse the 
data was obtained from the ONS Medical Research 
Service (MR1101, Nov 20, 2007) and from the statutory 
Patient Information Advisory Group (PIAG; now the 
Ethics and Conﬁ dentiality Committee of the National 
Information Governance Board) under Section 61 of the 
Health and Social Care Act 2001 (PIAG 1-05(c)/2007, 
July 31, 2007). Ethical approval for the study was obtained 
from the Ethics Committee of the London School of 
Hygiene and Tropical Medicine (LSHTM; number 5192, 
Sept 12, 2007) and the NHS South East Research Ethics 
Committee (07/MRE01/52, May 15, 2007).
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Figure 1: Structure of survival analyses in relation to NHS cancer plan, patients diagnosed 1996–2006 and 
followed up to 2007
Numbers in the cells indicate the minimum number of years of follow-up completed by patients surviving to the 
end of a given calendar year (columns) who were diagnosed in the index year (rows). In the cohort approach all 
patients diagnosed in a given period were followed up for at least 5 years. In the complete approach some patients 
were followed up for less than 5 years. In the hybrid approach survival is estimated from the most recent follow-up 
data (dashed lines). Conditional 5-year survival is restricted to those who had survived at least 1 year; ie, excluding 
follow-up in shaded cells.
See Online for webappendix
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Overall annual 
trend (%)*
Calendar period of diagnosis Change in annual trend between
1996–2000 2001–03 2004–06 1996–2000 and 2001–03 2001–03 and 2004–06
Survival (%) 
for 2000†
Annual 
trend (%)*
Survival (%) 
for 2003†
Annual 
trend (%)*
Survival (%) 
for 2006†
Annual 
trend (%)*
Change‡ (%) 95% CI Change‡ (%) 95% CI
England
Oesophagus
Men 1·2§ 32·9 1·4§ 36·5 1·1§ 39·7 1·0¶ –0·3 –1·1 to 0·6 0·0 –1·5 to 1·4
Women 1·0§ 29·9 1·3§ 32·4 0·6 34·5 0·7 –0·7 –1·7 to 0·4 0·1 –1·8 to 2·0
Stomach
Men 0·9§ 36·2 1·0§ 37·8 0·3 41·0 1·4¶ –0·7 –1·5 to 0·1 1·1 –0·3 to 2·6
Women 0·8§ 34·5 0·9§ 35·1 –0·2 38·4 1·7¶ –1·1 –2·1 to 0·0 1·9 0·0 to 3·8
Colon
Men 0·5§ 69·5 0·3¶ 69·9 0·0 73·0 1·5§ –0·3 –0·8 to 0·3 1·5 0·5 to 2·4
Women 0·5§ 67·6 0·5§ 67·9 –0·1 70·4 1·3§ –0·6 –1·2 to 0·0 1·4 0·4 to 2·4
Rectum
Men 0·5§ 76·4 0·5§ 77·1 0·1 79·3 1·0¶ –0·4 –1·0 to 0·2 0·9 –0·1 to 2·0
Women 0·4§ 75·6 0·6§ 75·8 –0·2 77·7 1·0¶ –0·8 –1·6 to 0·0 1·2 –0·1 to 2·5
Pancreas
Men 0·4§ 14·8 0·3 16·1 0·5 17·3 0·4 0·2 –0·6 to 1·0 –0·1 –1·4 to 1·2
Women 0·4§ 13·2 0·2 14·4 0·5¶ 16·4 0·7 0·3 –0·4 to 1·0 0·2 –1·0 to 1·5
Larynx
Men 0·0 84·0 –0·3 84·9 0·6 85·5 0·0 0·9 –0·2 to 2·0 –0·6 –2·4 to 1·3
Lung
Men 0·4§ 25·0 0·5§ 26·3 0·4¶ 26·5 –0·1 –0·2 –0·5 to 0·2 –0·4 –1·1 to 0·2
Women 0·5§ 26·7 0·7§ 28·8 0·7§ 29·1 –0·2 0·0 –0·5 to 0·5 –0·9 –1·7 to –0·2
Melanoma
Men 0·2§ 94·7 0·2 94·6 –0·1 95·9 0·7¶ –0·3 –0·9 to 0·2 0·9 0·1 to 1·7
Women 0·1 97·4 0·1 97·8 0·2 97·7 –0·2 0·1 –0·2 to 0·5 –0·4 –0·9 to 0·2
Breast
Women 0·3§ 95·1 0·3§ 96·0 0·3§ 96·6 0·2¶ 0·0 –0·2 to 0·1 –0·1 –0·3 to 0·1
Cervix
Women 0·3¶ 84·0 0·0 84·2 0·1 86·8 1·2¶ 0·1 –0·7 to 1·0 1·1 –0·3 to 2·6
Uterus
Women 0·4§ 88·9 0·5§ 89·2 –0·1 91·1 1·0§ –0·7 –1·2 to –0·1 1·1 0·3 to 2·0
Ovary
Women 0·5§ 67·3 0·4¶ 67·7 0·0 70·2 1·3¶ –0·4 –1·1 to 0·3 1·3 0·1 to 2·5
Prostate
Men 0·8§ 92·5 1·1§ 94·4 0·4§ 95·8 0·5§ –0·8 –1·0 to –0·5 0·1 –0·2 to 0·4
Testis
Men 0·1 98·5 0·2 98·0 –0·3¶ 98·4 0·4 –0·5 –0·9 to –0·1 0·7 0·0 to 1·4
Kidney
Men 0·4§ 66·4 0·5¶ 66·3 –0·3 68·5 1·2¶ –0·8 –1·7 to 0·2 1·5 –0·1 to 3·0
Women 0·8§ 64·4 1·0§ 63·7 –0·8 68·6 2·9§ –1·8 –3·1 to –0·6 3·7 1·7 to 5·7
Bladder
Men –0·6§ 78·4 –1·0§ 76·3 –0·5¶ 76·8 0·5 0·5 –0·2 to 1·1 1·0 –0·1 to 2·1
Women –0·8§ 65·8 –1·5§ 62·0 –1·1¶ 64·1 1·6¶ 0·4 –0·7 to 1·5 2·8 0·8 to 4·8
Brain
Men 0·5§ 30·9 0·1 31·0 0·0 35·8 2·4§ 0·0 –1·2 to 1·1 2·3 0·3 to 4·3
Women 0·2 30·2 0·5 30·5 –0·1 30·1 –0·1 –0·6 –2·0 to 0·7 0·0 –2·3 to 2·3
Hodgkin’s disease
Men –0·2 91·7 –0·1 89·4 –1·1¶ 90·0 0·8 –1·0 –2·3 to 0·3 1·9 –0·4 to 4·3
Women –0·3 93·2 0·6¶ 90·9 –1·5¶ 87·5 –1·0 –2·1 –3·6 to –0·7 0·5 –2·1 to 3·2
(Continues on next page)
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Overall annual 
trend (%)*
Calendar period of diagnosis Change in annual trend between
1996–2000 2001–03 2004–06 1996–2000 and 2001–03 2001–03 and 2004–06
Survival (%) 
for 2000†
Annual 
trend (%)*
Survival (%) 
for 2003†
Annual 
trend (%)*
Survival (%) 
for 2006†
Annual 
trend (%)*
Change‡ (%) 95% CI Change‡ (%) 95% CI
(Continued from previous page)
Non-Hodgkin lymphoma
Men 0·5§ 70·7 0·3 72·9 0·9§ 75·0 0·6 0·6 –0·2 to 1·4 –0·3 –1·6 to 1·0
Women 0·6§ 71·1 0·3 74·1 1·3§ 75·5 0·1 1·0 0·1 to 1·8 –1·2 –2·6 to 0·1
Myeloma
Men 0·3¶ 65·8 0·4 67·6 0·7 67·4 –0·5 0·3 –1·1 to 1·6 –1·2 –3·4 to 1·1
Women 0·7§ 64·4 0·6¶ 67·1 1·0¶ 68·6 0·2 0·4 –1·0 to 1·9 –0·8 –3·3 to 1·6
Leukaemia
Men –0·3¶ 64·4 –0·1 63·7 –0·3 62·1 –0·7 –0·2 –1·2 to 0·8 –0·4 –2·1 to 1·3
Women 0·0 60·5 0·0 59·0 –0·7 60·5 1·1 –0·7 –1·9 to 0·4 1·9 –0·1 to 3·9
Wales
Oesophagus
Men 1·8§ 35·8 2·6§ 39·1 0·3 43·2 1·9 –2·3 –5·6 to 1·0 1·5 –4·1 to 7·1
Women 1·1¶ 30·9 1·9¶ 33·7 0·5 34·2 0·0 –1·4 –5·4 to 2·6 –0·4 –7·6 to 6·7
Stomach
Men 0·5 36·2 1·1 39·1 0·9 36·4 –1·8 –0·3 –3·2 to 2·6 –2·6 –7·8 to 2·5
Women 0·2 30·9 –0·4 35·5 2·5 35·2 –1·4 2·9 –0·6 to 6·5 –3·9 –10·5 to 2·7
Colon
Men 0·6¶ 67·7 0·6 69·8 0·8 70·9 0·1 0·2 –1·9 to 2·3 –0·6 –4·1 to 2·8
Women 0·2 65·9 0·8 68·4 0·8 64·7 –2·3 0·0 –2·3 to 2·2 –3·1 –6·8 to 0·7
Rectum
Men 0·6¶ 75·9 1·3¶ 77·4 0·1 76·9 –0·3 –1·3 –3·6 to 1·1 –0·4 –4·3 to 3·6
Women 0·5 75·0 0·3 77·0 0·9 79·1 0·7 0·6 –2·5 to 3·6 –0·2 –5·4 to 5·0
Pancreas
Men 0·2 14·6 –0·3 15·3 0·5 17·3 0·7 0·8 –2·2 to 3·7 0·2 –4·9 to 5·4
Women 0·4 11·0 –0·2 15·0 2·1¶ 16·2 –0·5 2·3 –0·3 to 5·0 –2·6 –7·4 to 2·2
Larynx
Men –0·5 82·7 0·6 82·6 –0·4 75·3 –3·5 –1·0 –5·4 to 3·4 –3·1 –11·5 to 5·3
Lung
Men 0·4¶ 23·7 0·8¶ 25·2 0·4 24·8 –0·4 –0·5 –1·8 to 0·9 –0·7 –3·1 to 1·7
Women 0·5¶ 25·8 1·1¶ 29·9 1·5¶ 26·4 –2·5¶ 0·4 –1·3 to 2·2 –4·0 –6·9 to –1·1
Melanoma
Men 0·6 91·5 1·4¶ 90·9 –1·0 92·0 1·0 –2·4 –5·2 to 0·3 2·0 –1·9 to 6·0
Women 0·3 92·8 0·3 94·4 0·6 94·9 –0·1 0·3 –1·9 to 2·5 –0·7 –4·0 to 2·6
Breast
Women 0·4§ 92·7 0·3¶ 94·0 0·5¶ 95·7 0·6 0·1 –0·5 to 0·8 0·2 –0·9 to 1·2
Cervix
Women 0·6 77·2 –0·1 79·8 1·3 83·6 1·2 1·5 –2·1 to 5·0 –0·1 –5·8 to 5·6
Uterus
Women 0·4 87·9 0·3 88·3 0·0 90·5 1·1 –0·4 –2·4 to 1·7 1·1 –2·1 to 4·3
Ovary
Women 0·2 62·8 0·3 65·9 1·4 63·4 –2·0 1·2 –1·6 to 3·9 –3·4 –8·1 to 1·4
Prostate
Men 1·2§ 85·5 1·3§ 90·1 1·7§ 92·4 0·3 0·3 –0·7 to 1·4 –1·3 –2·8 to 0·1
Testis
Men –0·1 97·8 –0·1 97·7 0·0 97·5 –0·1 0·2 –1·9 to 2·2 –0·1 –4·0 to 3·7
Kidney
Men 0·4 65·2 0·7 67·3 0·7 66·0 –1·0 0·0 –3·5 to 3·5 –1·7 –7·4 to 3·9
Women 0·2 61·7 –0·1 65·7 2·1 64·4 –1·7 2·2 –2·4 to 6·9 –3·8 –11·0 to 3·4
(Continues on next page)
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Role of the funding source
This work was partly funded under a contract with the 
ONS (NT-04/2355A). The Cancer Survival Group (BR, 
UN, MQ, LE) at the LSHTM has been funded by Cancer 
Research UK (grant C1336/A5735) since April, 2005. 
Funding applications were open and competitive. The 
ONS collated the data from the regional registries and 
arranged their linkage to data on deaths at the National 
Health Service Central Register. Neither Cancer 
Research UK nor the ONS had any role in study design, 
data collection, analysis, interpretation of the data, or 
the writing of this article. MPC, BR, UN, MQ, LE, AS, 
CM, and SW had access to the raw data. The 
corresponding author had full access to all the data and 
the ﬁ nal responsibility to submit for publication.
Results
1-year survival improved for most cancers in patients 
diagnosed during 1996–2006 and followed until 2007, 
for both sexes and in England and Wales. For patients 
diagnosed in 2006, 1-year survival was over 60% for 25 
of the 35 cancer–sex combinations, both in England 
and Wales (table 2). For cancers of the oesophagus, 
stomach, pancreas, lung, and brain, 1-year survival was 
poor, in the range 15–20% (pancreas) and rarely over 
40%, despite noticeable improvement for some cancers 
(oesophagus, stomach, brain among men in England, 
oesophagus in Wales). Table 2 summarises temporal 
trends in 1-year survival, both for the entire period 
1996–2007 and in each of the three calendar periods.
For patients diagnosed in England during 1996–2000, 
before the NHS cancer plan, 1-year survival increased 
signiﬁ cantly (p<0·05) for eight of 17 cancers in men and 
for 12 of 18 cancers in women. The annual increase was 
about 1% for cancers of the oesophagus, stomach, and 
prostate in men, and for cancers of the oesophagus, 
stomach, and kidney among women. The pattern was 
similar in Wales, but the trends were statistically 
signiﬁ cant less often because of the much smaller 
population.
During 2001–03, survival for most cancers did not 
increase, or else the upward trends observed for 
1996–2000 were attenuated. This pattern was more 
marked in England, where upward trends slowed 
between these two periods for 21 of the 35 cancer–sex 
combinations, compared with 13 in Wales. The steep 
increase in 1-year survival for non-Hodgkin lymphoma 
is a notable exception: in Wales, 1-year survival rose by 
about 1% a year during 1996–2000, and by 2% a year 
during 2001–03 (1% a year in England).
For patients diagnosed during 2004–06, 1-year survival 
in England increased again for most cancers. The annual 
increase in survival was 1% or more for 15 of the 
35 cancer–sex combinations, although the increases 
Overall annual 
trend (%)*
Calendar period of diagnosis Change in annual trend between
1996–2000 2001–03 2004–06 1996–2000 and 2001–03 2001–03 and 2004–06
Survival (%) 
for 2000†
Annual 
trend (%)*
Survival (%) 
for 2003†
Annual 
trend (%)*
Survival (%) 
for 2006†
Annual 
trend (%)*
Change‡ (%) 95% CI Change‡ (%) 95% CI
(Continued from previous page)
Bladder
Men 0·0 85·2 0·0 85·7 0·2 85·1 –0·4 0·2 –1·5 to 1·9 –0·6 –3·4 to 2·3
Women 0·0 74·9 –0·1 74·8 0·0 74·8 0·0 0·1 –3·2 to 3·4 0·0 –5·5 to 5·5
Brain
Men 0·7 29·9 0·3 29·2 –0·5 36·1 3·7 –0·8 –5·0 to 3·4 4·2 –3·4 to 11·8
Women 0·8 34·3 1·9 33·3 –1·5 34·7 1·4 –3·4 –8·7 to 2·0 2·9 –6·2 to 12·0
Hodgkin’s disease
Men –1·7¶ 88·6 –1·6 89·1 1·0 78·1 –6·0 2·6 –2·8 to 8·0 –7·0 –17·7 to 3·8
Women –1·8 87·8 –0·8 89·6 1·3 73·2 –8·8 2·1 –5·3 to 9·4 –10·1 –29·6 to 9·4
Non-Hodgkin lymphoma
Men 1·0¶ 69·8 1·4 75·2 2·0 74·6 –1·3 0·6 –2·6 to 3·8 –3·3 –8·4 to 1·7
Women 1·0¶ 69·9 1·0 75·2 2·2 75·9 –0·7 1·2 –2·2 to 4·6 –2·9 –8·3 to 2·5
Myeloma
Men 1·7¶ 66·0 1·8 69·3 0·7 75·7 2·8 –1·1 –5·8 to 3·7 2·1 –5·9 to 10·1
Women 0·3 61·0 –0·7 65·8 2·8 66·7 –1·0 3·5 –1·7 to 8·6 –3·7 –12·2 to 4·8
Leukaemia
Men 0·8 62·8 1·1 60·7 –1·6 66·0 3·4 –2·6 –6·2 to 1·0 5·0 –1·0 to 10·9
Women 1·0¶ 58·1 1·2 59·6 0·2 63·1 1·6 –1·0 –5·2 to 3·2 1·4 –5·4 to 8·3
All patients were aged 15–99 years, were diagnosed from 1996 to 2006, and were followed up until 2007. *Mean annual change (%) in relative survival within each calendar period (absolute value). †Fitted 
estimate of relative survival for the last year of the calendar period. ‡Diﬀ erence in the year-on-year trends between successive calendar periods. §p<0·01. ¶p<0·05.
Table 2: 1-year relative survival (%) for patients diagnosed in selected years, and year-on-year trends (%) within calendar period of diagnosis and overall (1996–2006) for 21 common 
cancers in England and Wales
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Time since 
diagnosis (years)
Men Women
Relative survival (%) Annual change (%)* Survival (%) 
predicted for 
2007‡
Relative survival (%) Annual change (%)* Survival (%) 
predicted for 
2007‡
1996–
2000
2001–03 2004–06 2001–
03
2004–
06
Overall† 1996–
2000
2001–03 2004–06 2001–
03
2004–
06
Overall†
England
Oesophagus
3 11·0 13·9 15·5 0·7§ 0·5¶ 0·5§ 17·1 10·5 13·2 14·9 0·7§ 0·6¶ 0·5§ 16·3
5 7·9 10·4 ·· 0·6§ ·· ·· 13·0 8·0 10·3 ·· 0·6§ ·· ·· 12·1
5 (conditional) 26·2 28·9 ·· 0·7¶ ·· ·· 32·9 28·9 32·5 ·· 0·9¶ ·· ·· 35·1
10 6·2 ·· ·· ·· ·· ·· 10·7 6·5 ·· ·· ·· ·· ·· 9·3
Stomach
3 16·8 18·2 19·4 0·3¶ 0·4¶ 0·3§ 21·0 17·4 18·8 18·0 0·3¶ –0·3 0·1¶ 18·4
5 13·1 14·4 ·· 0·3¶ ·· ·· 16·5 14·1 15·4 ·· 0·3¶ ·· ·· 15·3
5 (conditional) 38·3 38·0 ·· –0·1 ·· ·· 40·2 43·5 43·2 ·· –0·1 ·· ·· 39·5
10 10·6 ·· ·· ·· ·· ·· 13·6 11·6 ·· ·· ·· ·· ·· 13·1
Colon
3 53·5 54·6 57·6 0·3¶ 1·0§ 0·3§ 58·8 52·5 53·8 55·9 0·3¶ 0·7§ 0·3§ 57·5
5 47·6 48·9 ·· 0·3¶ ·· ·· 53·4 47·6 49·2 ·· 0·4§ ·· ·· 52·7
5 (conditional) 69·1 70·1 ·· 0·3 ·· ·· 73·4 71·2 72·8 ·· 0·4¶ ·· ·· 74·7
10 43·2 ·· ·· ·· ·· ·· 48·7 44·2 ·· ·· ·· ·· ·· 49·5
Rectum
3 57·5 59·4 61·8 0·5§ 0·8§ 0·4§ 62·6 58·2 59·4 61·5 0·3 0·7¶ 0·3§ 62·1
5 49·6 51·9 ·· 0·6§ ·· ·· 54·3 51·2 53·6 ·· 0·6§ ·· ·· 56·0
5 (conditional) 65·7 67·4 ·· 0·4¶ ·· ·· 68·4 68·7 70·8 ·· 0·5¶ ·· ·· 72·2
10 42·8 ·· ·· ·· ·· ·· 47·7 45·8 ·· ·· ·· ·· ·· 50·1
Pancreas
3 3·9 4·1 5·0 0·0 0·3¶ 0·1¶ 5·1 3·4 3·9 4·1 0·1 0·1 0·1¶ 4·4
5 2·9 2·8 ·· 0·0 ·· ·· 3·7 2·3 2·7 ·· 0·1 ·· ·· 3·2
5 (conditional) 20·1 18·4 ·· –0·4 ·· ·· 22·1 18·4 19·3 ·· 0·2 ·· ·· 19·6
10 2·2 ·· ·· ·· ·· ·· 2·8 1·8 ·· ·· ·· ·· ·· 2·6
Larynx
3 70·6 70·8 73·2 0·0 0·8 0·2 74·9 ·· ·· ·· ·· ·· ·· ··
5 64·9 66·1 ·· 0·3 ·· ·· 70·4 ·· ·· ·· ·· ·· ·· ··
5 (conditional) 76·7 78·4 ·· 0·4 ·· ·· 82·0 ·· ·· ·· ·· ·· ·· ··
10 56·3 ·· ·· ·· ·· ·· 61·6 ·· ·· ·· ·· ·· ·· ··
Lung
3 8·7 9·2 9·7 0·1¶ 0·2¶ 0·1§ 9·7 9·7 11·3 11·5 0·4§ 0·1 0·2§ 11·4
5 6·2 6·6 ·· 0·1¶ ·· ·· 7·0 7·1 8·3 ·· 0·3§ ·· ·· 8·5
5 (conditional) 26·0 25·5 ·· –0·1 ·· ·· 26·5 28·3 29·4 ·· 0·3 ·· ·· 29·4
10 4·6 ·· ·· ·· ·· ·· 5·2 5·1 ·· ·· ·· ·· ·· 6·0
Melanoma
3 84·1 86·3 86·8 2·5§ 0·4 2·6§ 87·8 92·6 93·5 94·4 0·2¶ 0·3¶ 0·2§ 93·8
5 78·6 81·9 ·· 3·7§ ·· ·· 82·9 89·7 91·3 ·· 0·4§ ·· ·· 91·8
5 (conditional) 83·3 86·4 ·· 3·5§ ·· ·· 86·5 92·3 93·4 ·· 0·3¶ ·· ·· 94·1
10 73·4 ·· ·· ·· ·· ·· 78·2 86·3 ·· ·· ·· ·· ·· 88·6
Breast
3 ·· ·· ·· ·· ·· ·· ·· 86·4 88·7 90·4 0·6§ 0·6§ 0·4§ 90·7
5 ·· ·· ·· ·· ·· ·· ·· 80·6 83·7 ·· 0·8§ ·· ·· 86·0
5 (conditional) ·· ·· ·· ·· ·· ·· ·· 85·2 87·5 ·· 0·6§ ·· ·· 89·0
10 ·· ·· ·· ·· ·· ·· ·· 72·8 ·· ·· ·· ·· ·· 78·4
(Continues on next page)
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Time since 
diagnosis (years)
Men Women
Relative survival (%) Annual change (%)* Survival (%) 
predicted for 
2007‡
Relative survival (%) Annual change (%)* Survival (%) 
predicted for 
2007‡
1996–
2000
2001–03 2004–06 2001–
03
2004–
06
Overall† 1996–
2000
2001–03 2004–06 2001–
03
2004–
06
Overall†
(Continued from previous page)
Cervix
3 ·· ·· ·· ·· ·· ·· ·· 71·1 72·0 74·4 0·2 0·8¶ 0·3¶ 75·6
5 ·· ·· ·· ·· ·· ·· ·· 67·3 68·8 ·· 0·4¶ ·· ·· 72·1
5 (conditional) ·· ·· ·· ·· ·· ·· ·· 80·0 82·4 ·· 0·6§ ·· ·· 83·5
10 ·· ·· ·· ·· ·· ·· ·· 64·4 ·· ·· ·· ·· ·· 69·1
Uterus
3 ·· ·· ·· ·· ·· ·· ·· 78·7 80·5 81·3 0·5§ 0·3 0·3§ 82·5
5 ·· ·· ·· ·· ·· ·· ·· 75·0 77·0 ·· 0·5§ ·· ·· 78·6
5 (conditional) ·· ·· ·· ·· ·· ·· ·· 85·3 86·5 ·· 0·3¶ ·· ·· 86·3
10 ·· ·· ·· ·· ·· ·· ·· 71·6 ·· ·· ·· ·· ·· 75·2
Ovary
3 ·· ·· ·· ·· ·· ·· ·· 45·8 46·5 48·7 0·2 0·7§ 0·2§ 50·6
5 ·· ·· ·· ·· ·· ·· ·· 38·6 38·2 ·· –0·1 ·· ·· 42·1
5 (conditional) ·· ·· ·· ·· ·· ·· ·· 57·8 57·0 ·· –0·2 ·· ·· 59·5
10 ·· ·· ·· ·· ·· ·· ·· 33·3 ·· ·· ·· ·· ·· 36·1
Prostate
3 78·7 86·1 89·6 1·9§ 1·2§ 1·3§ 90·2 ·· ·· ·· ·· ·· ·· ··
5 71·4 81·5 ·· 2·5§ ·· ·· 86·2 ·· ·· ·· ·· ·· ·· ··
5 (conditional) 79·1 86·8 ·· 1·9§ ·· ·· 90·1 ·· ·· ·· ·· ·· ·· ··
10 59·8 ·· ·· ·· ·· ·· 75·7 ·· ·· ·· ·· ·· ·· ··
Testis ··
3 96·7 96·9 97·5 0·1 0·2 0·1 97·5 ·· ·· ·· ·· ·· ·· ··
5 96·3 96·7 ·· 0·1 ·· ·· 97·3 ·· ·· ·· ·· ·· ·· ··
5 (conditional) 98·1 98·3 ·· 0·0 ·· ·· 99·1 ·· ·· ·· ·· ·· ·· ··
10 96·0 ·· ·· ·· ·· ·· 96·5 ·· ·· ·· ·· ·· ·· ··
Kidney
3 52·7 52·7 54·5 0·0 0·6¶ 0·1 55·4 50·1 52·4 54·2 0·6¶ 0·6 0·4§ 55·9
5 47·0 47·5 ·· 0·1 ·· ·· 50·2 45·9 47·7 ·· 0·4 ·· ·· 51·3
5 (conditional) 71·5 72·0 ·· 0·1 ·· ·· 73·8 73·4 74·4 ·· 0·2 ·· ·· 74·9
10 40·1 ·· ·· ·· ·· ·· 43·3 39·6 ·· ·· ·· ·· ·· 43·9
Bladder
3 68·7 62·0 60·8 –1·7§ –0·4 –1·0§ 60·6 57·4 48·4 48·4 –2·2§ 0·0 –1·3§ 49·7
5 64·0 57·3 ·· –1·7§ ·· ·· 55·8 53·6 44·1 ·· –2·4§ ·· ·· 45·2
5 (conditional) 79·5 74·8 ·· –1·2§ ·· ·· 73·1 77·8 70·4 ·· –1·9§ ·· ·· 71·8
10 58·1 ·· ·· ·· ·· ·· 50·9 48·5 ·· ·· ·· ·· ·· 41·5
Brain
3 16·3 16·0 15·9 –0·1 0·0 0·0 17·5 17·1 16·2 17·5 –0·2 0·4 –0·1 17·7
5 12·4 12·5 ·· 0·0 ·· ·· 14·0 13·9 13·4 ·· –0·1 ·· ·· 14·2
5 (conditional) 40·3 40·0 ·· –0·1 ·· ·· 40·2 47·9 43·7 ·· –1·0¶ ·· ·· 48·1
10 7·9 ·· ·· ·· ·· ·· 9·1 9·6 ·· ·· ·· ·· ·· 9·7
Hodgkin’s disease
3 86·7 85·0 84·2 –0·4 –0·2 –0·3¶ 85·9 86·7 86·6 83·4 0·0 –1·1¶ –0·2 82·3
5 83·8 82·6 ·· –0·3 ·· ·· 84·1 83·0 83·6 ·· 0·1 ·· ·· 77·7
5 (conditional) 91·1 91·5 ·· 0·1 ·· ·· 93·8 90·3 90·6 ·· 0·1 ·· ·· 89·1
10 80·0 ·· ·· ·· ·· ·· 81·2 80·2 ·· ·· ·· ·· ·· 76·3
(Continues on next page)
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Time since 
diagnosis (years)
Men Women
Relative survival (%) Annual change (%)* Survival (%) 
predicted for 
2007‡
Relative survival (%) Annual change (%)* Survival (%) 
predicted for 
2007‡
1996–
2000
2001–03 2004–06 2001–
03
2004–
06
Overall† 1996–
2000
2001–03 2004–06 2001–
03
2004–
06
Overall†
(Continued from previous page)
Non-Hodgkin lymphoma
3 57·7 59·9 64·2 0·6§ 1·4§ 0·6§ 64·6 59·2 62·3 66·6 0·8§ 1·4§ 0·7§ 66·3
5 51·8 55·0 ·· 0·8§ ·· ·· 60·5 53·8 57·5 ·· 0·9§ ·· ·· 62·5
5 (conditional) 73·6 76·8 ·· 0·8§ ·· ·· 81·2 76·0 79·7 ·· 0·9§ ·· ·· 83·7
10 44·3 ·· ·· ·· ·· ·· 53·0 45·5 ·· ·· ·· ·· ·· 54·1
Myeloma
3 42·1 44·5 47·7 0·6¶ 1·1¶ 0·5§ 47·0 39·8 42·4 45·6 0·6¶ 1·0¶ 0·6§ 44·8
5 28·8 31·6 ·· 0·7¶ ·· ·· 35·9 26·7 29·2 ·· 0·6¶ ·· ·· 30·9
5 (conditional) 44·3 47·4 ·· 0·8¶ ·· ·· 54·1 42·1 44·4 ·· 0·6 ·· ·· 46·2
10 15·2 ·· ·· ·· ·· ·· 19·8 13·3 ·· ·· ·· ·· ·· 15·6
Leukaemia
3 50·0 50·0 49·9 0·0 0·0 0·0 49·3 46·3 46·5 47·2 0·1 0·2 0·1 47·3
5 42·7 43·6 ·· 0·2 ·· ·· 42·7 40·3 41·7 ·· 0·4 ·· ·· 42·7
5 (conditional) 66·3 68·2 ·· 0·5 ·· ·· 69·1 66·1 70·5 ·· 1·1§ ·· ·· 70·4
10 32·2 ·· ·· ·· ·· ·· 33·8 32·7 ·· ·· ·· ·· ·· 35·3
Wales
Oesophagus
3 12·4 16·5 14·4 1·0¶ –0·7 0·5¶ 14·5 12·4 16·5 14·4 1·0¶ –0·7 0·5¶ 14·3
5 10·8 11·7 ·· 0·2 ·· ·· 9·2 8·8 10·5 ·· 0·4 ·· ·· 12·2
5 (conditional) 34·3 30·5 ·· –0·9 ·· ·· 21·1 32·6 31·1 ·· –0·4 ·· ·· 34·3
10 7·5 ·· ·· ·· ·· ·· 7·0 6·9 ·· ·· ·· ·· ·· 8·9
Stomach
3 16·2 17·4 20·2 0·3 1·0 0·3 18·4 16·1 17·8 22·4 0·4 1·5 0·5¶ 24·8
5 12·7 14·3 ·· 0·4 ·· ·· 16·0 12·9 15·3 ·· 0·6 ·· ·· 19·9
5 (conditional) 38·1 36·2 ·· –0·5 ·· ·· 43·8 41·4 43·3 ·· 0·5 ·· ·· 55·4
10 11·2 ·· ·· ·· ·· ·· 12·6 10·4 ·· ·· ·· ·· ·· 15·4
Colon
3 51·7 54·4 56·3 0·7 0·6 0·5¶ 56·7 49·4 53·3 52·5 1·0¶ –0·3 0·5¶ 51·4
5 46·5 49·9 ·· 0·9 ·· ·· 51·7 44·1 47·8 ·· 0·9¶ ·· ·· 45·8
5 (conditional) 70·3 71·9 ·· 0·4 ·· ·· 73·5 68·6 71·2 ·· 0·7 ·· ·· 71·3
10 42·9 ·· ·· ·· ·· ·· 45·0 40·5 ·· ·· ·· ·· ·· 43·0
Rectum
3 52·8 57·9 58·0 1·3¶ 0·0 0·7¶ 58·0 56·7 58·7 62·0 0·5 1·1 0·5 58·9
5 46·4 48·5 ·· 0·5 ·· ·· 49·5 50·7 53·9 ·· 0·8 ·· ·· 56·3
5 (conditional) 63·6 62·0 ·· –0·4 ·· ·· 64·7 68·1 71·2 ·· 0·8 ·· ·· 72·1
10 41·1 ·· ·· ·· ·· ·· 42·6 44·6 ·· ·· ·· ·· ·· 48·8
Pancreas
3 5·6 4·4 5·0 –0·3 0·2 –0·1 5·0 3·6 4·4 5·0 0·2 0·2 0·2 3·3
5 4·5 3·5 ·· –0·3 ·· ·· 4·0 3·0 2·8 ·· –0·1 ·· ·· 2·0
5 (conditional) 29·9 22·4 ·· –1·9 ·· ·· 20·2 24·0 23·0 ·· –0·2 ·· ·· 12·9
10 3·5 ·· ·· ·· ·· ·· 3·1 2·4 ·· ·· ·· ·· ·· 1·6
Larynx
3 65·7 67·2 64·6 0·4 –0·9 0·1 62·4 ·· ·· ·· ·· ·· ·· ··
5 60·3 63·4 ·· 0·8 ·· ·· 54·7 ·· ·· ·· ·· ·· ·· ··
5 (conditional) 74·6 75·4 ·· 0·2 ·· ·· 72·4 ·· ·· ·· ·· ·· ·· ··
10 50·8 ·· ·· ·· ·· ·· 48·8 ·· ·· ·· ·· ·· ·· ··
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Time since 
diagnosis (years)
Men Women
Relative survival (%) Annual change (%)* Survival (%) 
predicted for 
2007‡
Relative survival (%) Annual change (%)* Survival (%) 
predicted for 
2007‡
1996–
2000
2001–03 2004–06 2001–
03
2004–
06
Overall† 1996–
2000
2001–03 2004–06 2001–
03
2004–
06
Overall†
(Continued from previous page)
Lung
3 8·0 9·4 9·4 0·4¶ 0·0 0·2¶ 9·7 8·8 12·6 12·0 1·0§ –0·2 0·5§ 11·8
5 5·9 6·5 ·· 0·1 ·· ·· 6·9 6·7 9·2 ·· 0·6¶ ·· ·· 9·4
5 (conditional) 27·2 25·1 ·· –0·5 ·· ·· 27·5 29·1 29·8 ·· 0·2 ·· ·· 36·2
10 4·6 ·· ·· ·· ·· ·· 5·2 4·6 ·· ·· ·· ·· ·· 6·5
Melanoma
3 74·0 79·2 81·2 1·3 0·7 0·9¶ 81·0 85·9 86·6 91·1 0·2 1·5¶ 0·4 91·3
5 69·8 73·7 ·· 1·0 ·· ·· 72·1 81·6 83·3 ·· 0·4 ·· ·· 90·1
5 (conditional) 78·7 81·1 ·· 0·6 ·· ·· 78·2 89·1 88·3 ·· –0·2 ·· ·· 95·9
10 62·5 ·· ·· ·· ·· ·· 67·5 78·4 ·· ·· ·· ·· ·· 83·5
Breast
3 ·· ·· ·· ·· ·· ·· ·· 83·2 86·7 88·7 0·9§ 0·7¶ 0·6§ 90·4
5 ·· ·· ·· ·· ·· ·· ·· 77·9 82·3 ·· 1·1§ ·· ·· 85·5
5 (conditional) ·· ·· ·· ·· ·· ·· ·· 84·8 87·7 ·· 0·7§ ·· ·· 89·2
10 ·· ·· ·· ·· ·· ·· ·· 71·5 ·· ·· ·· ·· ·· 80·2
Cervix
3 ·· ·· ·· ·· ·· ·· ·· 63·2 64·3 66·1 0·3 0·6 0·3 72·0
5 ·· ·· ·· ·· ·· ·· ·· 58·6 61·8 ·· 0·8 ·· ·· 69·3
5 (conditional) ·· ·· ·· ·· ·· ·· ·· 75·1 80·3 ·· 1·3 ·· ·· 80·0
10 ·· ·· ·· ·· ·· ·· ·· 56·1 ·· ·· ·· ·· ·· 64·4
Uterus
3 ·· ·· ·· ·· ·· ·· ·· 77·5 79·1 79·2 0·4 0·0 0·2 80·8
5 ·· ·· ·· ·· ·· ·· ·· 74·1 75·2 ·· 0·3 ·· ·· 78·2
5 (conditional) ·· ·· ·· ·· ·· ·· ·· 84·9 85·8 ·· 0·2 ·· ·· 86·8
10 ·· ·· ·· ·· ·· ·· ·· 71·1 ·· ·· ·· ·· ·· 76·1
Ovary
3 ·· ·· ·· ·· ·· ·· ·· 42·7 44·5 47·7 0·4 1·1 0·4 44·2
5 ·· ·· ·· ·· ·· ·· ·· 36·4 37·7 ·· 0·3 ·· ·· 37·1
5 (conditional) ·· ·· ·· ·· ·· ·· ·· 58·7 58·2 ·· –0·1 ·· ·· 59·3
10 ·· ·· ·· ·· ·· ·· ·· 30·8 ·· ·· ·· ·· ·· 32·3
Prostate
3 70·4 80·0 86·0 2·4§ 2·0§ 1·7§ 85·2 ·· ·· ·· ·· ·· ·· ··
5 63·3 76·4 ·· 3·3§ ·· ·· 82·8 ·· ·· ·· ·· ·· ·· ··
5 (conditional) 76·3 86·4 ·· 2·5§ ·· ·· 90·2 ·· ·· ·· ·· ·· ·· ··
10 53·5 ·· ·· ·· ·· ·· 74·2 ·· ·· ·· ·· ·· ·· ··
Testis
3 95·4 96·4 94·8 0·2 –0·5 0·0 94·3 ·· ·· ·· ·· ·· ·· ··
5 95·4 96·2 ·· 0·2 ·· ·· 93·5 ·· ·· ·· ·· ·· ·· ··
5 (conditional) 98·2 98·6 ·· 0·1 ·· ·· 99·1 ·· ·· ·· ·· ·· ·· ··
10 95·3 ·· ·· ·· ·· ·· 92·8 ·· ·· ·· ·· ·· ·· ··
Kidney
3 51·3 53·4 55·6 0·5 0·7 0·4 52·5 52·4 51·5 58·4 –0·2 2·3 0·3 56·1
5 46·0 48·0 ·· 0·5 ·· ·· 47·1 48·4 50·5 ·· 0·5 ·· ·· 52·5
5 (conditional) 71·5 74·1 ·· 0·7 ·· ·· 72·7 77·9 81·0 ·· 0·8 ·· ·· 79·5
10 40·3 ·· ·· ·· ·· ·· 42·0 42·2 ·· ·· ·· ·· ·· 43·8
(Continues on next page)
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were not always statistically signiﬁ cant. In Wales, by 
contrast, survival fell for 19 of the 35 cancer–sex 
combinations, although none of the declines were 
signiﬁ cant.
Another way to summarise the contrast is to examine 
the diﬀ erences between England and Wales in survival 
trends within each of the three periods. During 
1996–2000, the annual increase in 1-year survival was 
greater in Wales than in England for 14 of 17 cancers in 
men and eight of 18 cancers in women. The situation 
was similar during 2001–03, with survival trends for 
eight of 17 cancers in men and 16 of 18 cancers in 
women in Wales slightly more favourable than in 
England and only seven less favourable. However, this 
pattern was reversed during 2004–06, when annual 
trends in England were more favourable than in Wales 
for 11 of 17 cancers in men and 12 of 18 cancers in 
women.
Longer-term survival was estimated for each calendar 
period and predicted for 2007, as was the change in 
survival between successive periods (table 3). 
In England, both 3-year and 5-year survival improved 
Time since 
diagnosis (years)
Men Women
Relative survival (%) Annual change (%)* Survival (%) 
predicted for 
2007‡
Relative survival (%) Annual change (%)* Survival (%) 
predicted for 
2007‡
1996–
2000
2001–03 2004–06 2001–
03
2004–
06
Overall† 1996–
2000
2001–03 2004–06 2001–
03
2004–
06
Overall†
(Continued from previous page)
Bladder
3 76·3 74·9 76·6 –0·3 0·6 –0·1 77·8 66·3 66·4 67·0 0·0 0·2 0·0 68·8
5 71·8 72·4 ·· 0·2 ·· ·· 74·9 63·3 63·5 ·· 0·0 ·· ·· 65·0
5 (conditional) 84·0 85·9 ·· 0·5 ·· ·· 87·6 84·0 85·8 ·· 0·4 ·· ·· 87·3
10 66·4 ·· ·· ·· ·· ·· 70·0 59·3 ·· ·· ·· ·· ·· 61·6
Brain
3 18·6 18·3 15·5 –0·1 –1·0 –0·2 17·3 20·8 18·9 20·5 –0·5 0·5 –0·2 19·1
5 14·2 14·2 ·· 0·0 ·· ·· 12·5 19·0 15·9 ·· –0·8 ·· ·· 16·4
5 (conditional) 46·0 45·6 ·· –0·1 ·· ·· 35·2 60·9 47·6 ·· –3·3¶ ·· ·· 44·0
10 9·8 ·· ·· ·· 9·6 13·2 ·· ·· ·· ·· ·· 11·9
Hodgkin’s disease
3 82·7 83·5 77·6 0·2 –2·0 –0·2 75·8 80·1 82·3 78·9 0·6 –1·1 0·1 87·6
5 78·1 81·4 ·· 0·8 ·· ·· 70·6 || || ··  || ·· ·· 87·6
5 (conditional) 86·3 91·7 ·· 1·3 ·· ·· 93·3 || || ··  || ·· ·· 90·6
10 74·0 ·· ·· ·· ·· ·· 67·7 72·0 ·· ·· ·· ·· ·· 83·8
Non-Hodgkin lymphoma
3 52·5 64·8 64·9 3·1§ 0·0 1·8§ 62·8 54·2 61·6 66·3 1·9¶ 1·6 1·3§ 65·6
5 44·8 57·9 ·· 3·3§ ·· ·· 57·1 49·5 57·5 ·· 2·0¶ ·· ·· 61·5
5 (conditional) 67·5 78·1 ·· 2·6§ ·· ·· 77·4 72·8 79·3 ·· 1·6¶ ·· ·· 81·9
10 36·7 ·· ·· ·· ·· ·· 43·3 43·4 ·· ·· ·· ·· ·· 55·1
Myeloma
3 36·5 45·4 49·8 2·2¶ 1·5 1·5¶ 46·0 40·9 41·2 41·2 0·1 0·0 0·0 35·2
5 25·3 34·9 ·· 2·4¶ ·· ·· 36·8 27·4 27·6 ·· 0·1 ·· ·· 22·4
5 (conditional) 40·7 51·8 ·· 2·8¶ ·· ·· 51·2 43·2 44·9 ·· 0·4 ·· ·· 32·4
10 12·4 ·· ·· ·· ·· ·· 20·7 14·1 ·· ·· ·· ·· ·· 7·5
Leukaemia
3 45·5 47·4 46·2 0·5 –0·4 0·2 48·3 45·1 46·7 50·6 0·4 1·3 0·5 51·4
5 38·4 41·1 ·· 0·7 ·· ·· 45·3 38·5 41·0 ·· 0·6 ·· ·· 40·7
5 (conditional) 63·6 65·5 ·· 0·5 ·· ·· 69·1 70·2 66·7 ·· –0·9 ·· ·· 63·3
10 27·8 ·· ·· ·· ·· ·· 35·9 32·0 ·· ·· ·· ·· ·· 33·4
All patients were adults aged 15–99 years, were diagnosed between 1996 and 2006 in England and Wales, and were followed up to 2007. *Mean annual change (%) in relative survival since previous calendar 
period. †Annual change (%) in relative survival over the three periods. ‡Survival predicted for patients diagnosed in 2007 using the hybrid approach (see text). §p<0·01. ¶p<0·05. ||Not enough data to be 
estimated.
Table 3: National trends in relative survival (%) at 3, 5, and 10 years after diagnosis, and 5-year conditional survival, by sex and calendar period of diagnosis, and predicted survival 
for 2007
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between 1996–2000 and 2001–03 for most tumours, 
except those of the bladder and brain (both sexes), and 
Hodgkin’s disease (men only). The picture in Wales 
was similar, but there was no improvement for tumours 
of the bladder or brain in men, or for tumours of the 
kidney or brain in women. The improvements in 
longer-term survival are similar to the earlier increases 
in 1-year survival in both countries.
Changes in 3-year survival between 2001–03 and 
2004–06 in both England and Wales were similar to those 
observed between 1996–2000 and 2001–03, with no clear 
trend emerging. The changes in 3-year survival were also 
compared between England and Wales. Between the 
periods 1996–2000 and 2001–03, survival increased more 
quickly in Wales than in England for 12 of 17 cancers in 
men and 13 of 18 cancers in women. Diﬀ erences between 
Wales and England in survival trends between 2001–03 
and 2004–06 were much less obvious for men, but the 
pattern was unchanged for women. The diﬀ erent timing 
of increases in 3-year survival between England and 
Leukaemia
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Figure 2: 3-year relative survival (%) for adults diagnosed with 21 common cancers during 1996–2000 and 2004–06 in England and Wales
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Wales produced similar overall changes during 
1996–2006, as shown for each sex in ﬁ gure 2.
The North–South gradient in cancer survival in 
England31 is only partially conﬁ rmed. The gradient was 
present in the case of colon cancer, but it has been 
attenuated by increases in survival in so-called low-
survival regions over the period 1996–2006 (table 4). 
Even so, the funnel plots show that the South West 
region (ﬁ gure 3, symbol K) was still a high-survival 
outlier in 2004–06, while the North West region 
(ﬁ gure 3, symbol B) was still a low-survival outlier.
Very little regional variation in breast-cancer survival 
was seen in England, where 1-year survival was close to 
95% for women diagnosed during 1996–2000 and 96% 
for those diagnosed in 2001–03, and 92% and 94%, 
respectively, in Wales (table 4). Even so, survival 
continued to increase in most regions, although in the 
North West the annual trend decelerated by 1% between 
2001–03 and 2004–06. 1-year survival for women 
diagnosed in each of the English regions during 
2004–06 is tightly clustered around 96% (ﬁ gure 3). 
Survival in the North West (ﬁ gure 3, symbol B) is lower 
than the pooled English value: the diﬀ erence is small, 
but the value is below the 99·8% control limits, and the 
downward annual trend during 2004–06 is outside the 
control limit. 1-year survival in Wales (ﬁ gure 3, symbol 
W) during 2004–06 was also below the control limits, 
but the year-on-year trend during that period was 
positive, and within the control limits.
Despite gradual improvement, 1-year relative survival 
from lung cancer remains poor, around 27% for men 
diagnosed during 2004–06 (table 4). 1-year survival in 
the Yorkshire and Humber region (ﬁ gure 3, symbol D) 
and Wales (ﬁ gure 3, symbol W) was below the lower 
95% control limit in that period, whereas survival in the 
London region (ﬁ gure 3, symbol H) was above the 
upper limit. Again, the annual trend in the North West 
region (ﬁ gure 3, symbol B) during 2004–06 was just 
below the lower 95% control limit, whereas the trend in 
the West Midland region (ﬁ gure 3, symbol F) was above 
the upper limit.
Discussion
Cancer survival, especially at 1 year after diagnosis, 
improved for most of the 21 cancers examined, both in 
England and Wales, during the period 1996–2007. Two 
distinct groups of cancers emerge from this analysis. 
The ﬁ rst group, with a generally poor prognosis, 
consists of ﬁ ve cancers for which 1-year survival is often 
below 40% in men and women: cancers of the 
oesophagus, stomach, pancreas, lung, and brain. 
Survival from cancers of the pancreas and lung has 
hardly improved at all between 1996–2007, and 1-year 
survival for pancreatic cancer remains below 20%. For 
the 25 remaining cancer–sex combinations, short-term 
prognosis is moderate or good, with 1-year survival over 
60%. The gap of 20% or more in 1-year survival between 
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these two groups of cancers is striking and persistent. 
The range of survival in the group of cancers with 
higher survival has tended to narrow over time, because 
of a ceiling eﬀ ect among malignancies for which 1-year 
survival is already 90% or higher: melanoma of the skin 
and cancers of the breast, uterus, prostate, and testis, 
and in England only, Hodgkin’s disease. Part of the 
increase in survival for prostate cancer may be 
attributable to the diagnosis of more indolent tumours 
as a result of widespread prostate-speciﬁ c antigen (PSA) 
testing.
A key aim of the NHS cancer plan for England, published 
in September, 2000, was to improve the prospects of 
survival for cancer patients. This study examines survival 
trends for 21 common cancers in England and Wales up to 
2007. The availability of 6 years of data on incident cancers 
in both England and Wales since the publication of the 
cancer plan provided an early opportunity to examine its 
eﬀ ect. The nearest equivalent cancer strategy for Wales, 
Designed to Tackle Cancer,5 was not published until 
December, 2006, so survival trends in Wales oﬀ er an 
interesting comparison with trends in England.
Men Women
Period of diagnosis* Change in annual trend (%)† Period of diagnosis* Change in annual trend (%)†
1996–2000 2001–03 2004–06 2001–03 2004–06 Overall 1996–2000 2001–03 2004–06 2001–03 2004–06 Overall
Colon
England 68·8 69·9 71·5 –0·3 1·5‡ 1·2§ 66·6 68·0 69·1 –0·6‡ 1·4‡ 0·8‡
North East 68·1 68·5 70·3 –0·6 2·8 2·2 64·2 66·7 66·9 –3·0‡ 5·2‡ 2·2
North West 66·6 70·0 70·3 –1·4 1·0 –0·4 64·1 68·3 66·9 –1·4 –1·4 –2·9‡
Yorkshire and 
Humber
67·7 68·8 70·3 0·4 –0·3 0·2 65·3 66·8 69·3 –0·2 1·9 1·7
East Midlands 66·7 68·6 69·5 –1·1 2·1 1·0 64·4 66·6 68·1 –1·4 2·9 1·5
West Midlands 67·7 70·2 73·4 –0·1 1·5 1·4 66·1 68·4 70·9 –0·8 2·5 1·8
East of England 71·6 70·6 72·1 0·2 1·8 2·0‡ 67·9 67·7 70·5 –0·3 3·7‡ 3·4‡
London 69·9 68·6 72·0 1·6 0·8 2·4‡ 67·3 65·3 67·7 1·6 0·3 1·9
South East 70·3 69·5 71·5 0·7 1·0 1·7‡ 69·0 69·0 69·4 0·1 0·2 0·3
South West 70·8 72·9 73·3 –1·9‡ 3·2‡ 1·3 69·1 71·1 71·0 –1·1 0·9 –0·3
Wales 66·5 69·1 70·7 0·2 –0·6 –0·5 64·3 67·6 66·9 0·0 –3·1 –3·1‡
Rectum
England 75·4 77·0 78·2 –0·4 0·9 0·6 74·4 76·0 76·7 –0·8‡ 1·2 0·4
North East 73·6 75·5 78·1 0·5 0·0 0·5 73·0 75·5 76·8 0·5 –1·8 –1·3
North West 72·7 76·8 78·1 –0·2 –1·1 –1·4 71·5 74·4 74·1 0·1 –2·7 –2·6‡
Yorkshire and 
Humber
75·9 76·4 78·2 –0·8 3·3‡ 2·5‡ 73·8 75·7 75·8 –2·7‡ 4·8‡ 2·1
East Midlands 75·0 75·5 75·8 –1·0 2·3 1·3 72·7 74·8 74·3 –1·8 2·0 0·2
West Midlands 74·4 76·4 78·2 –0·4 1·1 0·8 74·5 77·0 77·4 0·2 –1·9 –1·7
East of England 76·5 79·1 79·4 –0·9 0·5 –0·4 77·3 77·9 78·8 –1·8 4·6‡ 2·8‡
London 75·5 75·3 76·0 0·1 0·7 0·8 74·0 73·4 73·6 –0·7 2·2 1·4
South East 77·3 78·4 80·0 0·1 0·4 0·5 75·6 76·1 77·2 –0·3 1·3 1·0
South West 77·8 79·0 79·2 –1·2 2·0 0·8 77·3 79·8 82·0 –0·5 1·5 1·0
Wales 73·3 77·3 77·2 –1·3 –0·4 –1·6 74·4 76·1 78·5 0·6 –0·2 0·4
Prostate
England 90·2 94·0 95·3 –0·8§ 0·1 –0·6§ ·· ·· ·· ·· ·· ··
North East 91·0 95·5 96·2 –1·0‡ –0·5 –1·5‡ ·· ·· ·· ·· ·· ··
North West 88·5 93·1 95·0 –0·2 –1·1‡ –1·4§ ·· ·· ·· ·· ·· ··
Yorkshire and 
Humber
89·5 94·5 95·5 –1·3§ 0·3 –1·0‡ ·· ·· ·· ·· ·· ··
East Midlands 86·2 91·6 93·7 –1·1‡ 0·5 –0·6 ·· ·· ·· ·· ·· ··
West Midlands 90·5 95·2 97·2 –0·7‡ 0·1 –0·6 ·· ·· ·· ·· ·· ··
East of England 92·2 94·8 96·1 –0·1 –0·4 –0·5 ·· ·· ·· ·· ·· ··
London 93·4 93·9 95·5 0·3 0·5 0·8‡ ·· ·· ·· ·· ·· ··
South East 90·8 94·0 94·8 –0·8‡ 0·3 –0·5 ·· ·· ·· ·· ·· ··
South West 88·8 93·9 94·2 –2·1§ 1·1‡ –1·0‡ ·· ·· ·· ·· ·· ··
Wales 82·9 88·5 92·1 0·3 –1·3 –1·0 ·· ·· ·· ·· ·· ··
(Continues on next page)
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Survival is very similar in England and Wales, but the 
temporal pattern of change clearly diﬀ ers after 2001. On 
average, the gains in 1-year survival were more marked 
in Wales during 1996–2000 and 2001–03, whereas gains 
in England were more marked from 2004. For a number 
of cancers including stomach, colon, rectum, cervix, 
uterus, ovary, and kidney, survival trends in England 
improved between 2001–03 and 2004–06 in the absence 
of screening or the widespread delivery of more eﬀ ective 
new treatments. The diﬀ erent time trends in England 
and Wales suggest that those recent gains might be 
attributable to improvements in cancer care, including 
earlier diagnosis and more widespread adherence to 
treatment guidelines. The earlier improvement in 
Wales correlates with the timing of clinicians 
implementing the recommendations in the Cameron 
report4 from 1997. Although cancer services in Wales 
undoubtedly improved after the publication of the 
Cameron report, clinical cancer outcomes and cancer 
information were not given such high priority by 
hospital trusts as in England after the publication of the 
NHS cancer plan.
We identiﬁ ed no diﬀ erence between England and 
Wales in survival trends at 3 years or more after diagnosis 
for patients diagnosed up to 2003. 3-year survival 
increased slightly more in England than in Wales between 
2001–03 and 2004–06. The more rapid increase in short-
term survival in England than in Wales since 2004 could 
be interpreted as related to the cancer plan, but we do not 
have evidence of the extent to which the various initiatives 
in the cancer plan were fully implemented by that time. 
Even so, predicted 3-year survival for cancers diagnosed 
in 2007 in England was generally higher than for 2004–06, 
suggesting that survival is likely to continue to increase. 
By contrast, there are fewer predicted improvements in 
survival in Wales.
One aspect that suggests the results are plausible is 
the similarity of survival patterns between men and 
Men Women
Period of diagnosis* Change in annual trend (%)† Period of diagnosis* Change in annual trend (%)†
1996–2000 2001–03 2004–06 2001–03 2004–06 Overall 1996–2000 2001–03 2004–06 2001–03 2004–06 Overall
(Continued from previous page)
Breast
England ·· ·· ·· ·· ·· ·· 94·5 95·7 96·5 0·0 –0·1 –0·1
North East ·· ·· ·· ·· ·· ·· 94·3 96·4 96·9 –0·4 –0·1 –0·5
North West ·· ·· ·· ·· ·· ·· 93·8 95·5 95·7 –0·1 –0·9‡ –1·0§
Yorkshire and 
Humber
·· ·· ·· ·· ·· ·· 95·1 96·2 96·2 –0·4 0·0 –0·4
East Midlands ·· ·· ·· ·· ·· ·· 93·9 95·6 96·2 –0·3 0·0 –0·3
West Midlands ·· ·· ·· ·· ·· ·· 94·4 96·0 96·5 –0·4 0·2 –0·2
East of England ·· ·· ·· ·· ·· ·· 95·7 96·0 96·7 0·1 0·2 0·3
London ·· ·· ·· ·· ·· ·· 95·0 95·2 96·7 0·6‡ –0·1 0·5‡
South East ·· ·· ·· ·· ·· ·· 95·3 95·9 96·7 0·1 0·2 0·3
South West ·· ·· ·· ·· ·· ·· 93·0 94·9 96·8 0·3 –0·3 0·0
Wales ·· ·· ·· ·· ·· ·· 92·1 93·5 95·1 0·1 0·2 0·3
Lung
England 23·9 25·9 26·6 –0·2 –0·4 –0·6‡ 25·2 28·1 29·3 0·0 –0·9‡ –0·9‡
North East 24·6 26·5 26·7 0·4 –2·0 –1·6 26·2 28·9 29·0 –0·7 –0·2 –1·0
North West 22·1 25·5 26·1 0·1 –2·1‡ –2·0§ 23·7 27·0 28·9 0·3 –1·3 –1·0
Yorkshire and 
Humber
23·8 25·2 25·4 –0·5 0·3 –0·2 25·4 28·5 28·6 0·8 –3·9§ –3·2§
East Midlands 22·0 25·6 26·2 –0·9 –0·1 –1·0 24·6 26·3 27·7 –0·8 2·0 1·2
West Midlands 24·0 25·1 26·9 –0·4 1·9 1·5‡ 24·7 27·2 31·7 –0·1 2·8‡ 2·7‡
East of England 25·0 25·8 26·7 0·0 0·3 0·3 24·6 28·6 28·4 –0·7 –1·7 –2·4‡
London 26·9 27·3 28·3 0·9 –1·4 –0·5 28·1 30·9 32·0 –0·1 –0·8 –0·9
South East 23·6 25·1 25·9 0·4 –1·3 –0·8 24·2 26·5 28·2 0·8 –1·8 –1·0
South West 24·1 27·6 27·6 –1·7‡ 1·4 –0·3 25·9 29·1 29·9 –0·6 –0·4 –1·0
Wales 22·1 24·9 25·2 –0·5 –0·7 –1·2 23·6 28·3 28·9 0·4 –4·0‡ –3·6§
English regions correspond with the government oﬃ  ce regions of England. All patients were adults aged 15–99 years, were diagnosed between 1996–2006, and were followed up until 2007. *Fitted estimate of 
relative survival at the mid-point of the calendar period. †A negative value implies deceleration in the year-on-year trends between successive calendar periods. A positive value implies acceleration. The overall 
value compares the trend in 2004–06 with the trend in 1996–2000. ‡p<0·05. §p<0·01.
Table 4: Regional trends in relative survival (%) at 1 year after diagnosis, and year-on-year change (%), by sex and calendar period of diagnosis for selected cancers
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women in each country. Thus, the recent upward trend 
in 1-year survival in England occurred in both sexes, 
while a levelling oﬀ  of the trends was also seen in both 
sexes in Wales. The use in all analyses of region-speciﬁ c 
and deprivation-speciﬁ c life tables for each calendar 
year and each sex ensured that the background mortality 
used to estimate relative survival corresponded as 
closely as is feasible to that of each cancer patient.
Socioeconomic inequalities in survival have been 
widening for many adult cancers in England and Wales.8 
The NHS cancer plan aimed to reduce socioeconomic 
inequalities (the deprivation gap) in survival. Although 
that objective has not yet been fully assessed, and 
despite real recent improvements in 1-year survival in 
some of the more deprived regions, the previously 
described North–South gradient for cancer survival33 
and other socioeconomic and health-related para-
meters18 is still present, and relative survival for most 
cancers in the more aﬄ  uent southern regions is 
generally higher than the mean survival for England. 
The funnel plots presented in ﬁ gure 3 (and webappendix) 
provide insight into regional variation in survival and 
whether recent trends will enable regions with low 
survival to catch up. To the extent that gains in survival 
are less marked among more deprived groups than 
more aﬄ  uent groups, this will reduce the overall 
national trends in survival, and thus the overall 
eﬀ ectiveness of the plan.
The survival estimates reported here are not age-
standardised because the age distribution of cancer 
patients was fairly stable for most cancers during this 
short period (11 years). Age-standardised survival 
analyses showed almost no eﬀ ect on the estimation of 
survival or trends in survival (data not shown). A notable 
exception was Hodgkin’s disease, for which the marked 
fall in survival during 2004–06 was partly due to an 
increase in the age at diagnosis of patients diagnosed 
with this malignancy: the mean age at diagnosis 
increased by about 3 years between 1998 and 2005. 
Incidence of the 21 cancers examined was generally 
stable over the period 1996–2006, except for a rise in 
cancers of the prostate and breast, and melanoma of 
the skin, and a fall in cancers of the lung and stomach 
in men. Recorded incidence and survival have fallen for 
bladder cancer in England, but not in Wales (ﬁ gure 2). 
The fall in survival in England is mainly attributable to 
progressive change in the recorded spectrum of 
urothelial malignancies, following changes in 
pathological classiﬁ cation and coding34 that have not yet 
occurred to the same extent in Wales.
Patients who had previously had a primary malignancy 
in a diﬀ erent organ or tissue were included in these 
analyses, by contrast with our previous work.23,35 This 
was done mainly because of the marked increase of 
asymptomatic prostate cancer detected by PSA, since 
these men have extremely high survival, which would 
artiﬁ cially raise the proportion of patients excluded for 
a previous primary cancer. Survival estimates were 
virtually identical with and without the exclusion of 
patients with more than one tumour (data not shown).
In the past, patients who died on the date of diagnosis 
could not be distinguished in the national cancer 
registry data from DCO registrations, for which the true 
duration of survival is unknown.9 A ﬂ ag to indicate 
DCO status is now available for more than 90% of 
cancers registered since 1996 in England and Wales, 
but we excluded both DCO registrations and other cases 
with zero recorded survival, for consistency with most 
other publications on cancer survival. Inclusion of 
those patients who do appear to have died on the same 
day as the diagnosis (no DCO ﬂ ag) would have reduced 
the estimates of 1-year survival for some cancers by up 
to 1%, but it had no eﬀ ect on the estimated trends in 
survival (data not shown).
Successive EUROCARE studies have shown that 
cancer survival in both England and Wales has lagged 
behind other countries in western and northern Europe, 
despite encouraging recent results showing that both 
countries have tended to approach the levels of survival 
in other European countries during 1995–2002.36 The 
EUROCARE studies formed part of the impetus to 
create the NHS cancer plan.2 A recent editorial37 
questioned whether the UK really has an eﬀ ective 
cancer plan, on the basis of ﬁ ndings in the EUROCARE-4 
study,36 which included patients diagnosed up to 2002. 
Results from EUROCARE are in agreement with our 
own ﬁ ndings, particularly for cancers of moderate and 
good prognosis. However, the NHS cancer plan only 
dates from 2000, so the EUROCARE-4 study cannot 
oﬀ er a fully viable European comparison of survival 
trends after its implementation.
1-year survival is the only cohort-based measure of 
outcome that is available for the whole period up to 
2006. Even 3-year survival can only be estimated for 
patients diagnosed during 2004–06 by using the 
complete approach, and no estimation of 5-year survival 
for 2004–06 is currently possible without using the 
hybrid approach to incorporate follow-up data for 
patients who were diagnosed (and whose treatment will 
have begun) in earlier periods (ﬁ gure 1). 1-year survival 
is nevertheless a valuable public-health measure. 
International diﬀ erences38 and, in England and Wales, 
socioeconomic diﬀ erences23 in 5-year survival are largely 
attributable to higher cancer-related mortality soon 
after diagnosis.
The data analysed here represent the earliest period 
from which an overall assessment of survival trends 
after implementation of the cancer plan could 
reasonably be attempted. Recent survival trends in 
England, more favourable than those in Wales, do 
indicate that the NHS cancer plan is having some 
beneﬁ cial eﬀ ect in England.
Our ﬁ ndings do not, however, provide a deﬁ nitive 
verdict on the overall eﬀ ectiveness of the cancer plan. 
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The national data include over 2 million cancer patients 
and they are remarkably up to date, with follow-up data 
available to Dec 31, 2007. But even with a large and 
timely dataset, and the latest techniques to assess recent 
survival trends, it seems we will need at least 3 years of 
follow-up data for all patients diagnosed during the 
period 2004–06, up to the end of 2009. The ﬁ ndings 
also need to be extended for a longer period after the 
implementation of the cancer plan (patients diagnosed 
in 2007 or later). Future survival analyses for Wales 
should also provide further information on the overall 
eﬃ  cacy of cancer plans. Scotland implemented a 
strategic cancer plan in 2001,39 while Northern Ireland 
has not yet done so. Incorporation of survival trends in 
Scotland and Northern Ireland in the same analytical 
strategy might improve the evaluation of national 
cancer plans in the UK.
Finally, it is essential to do more detailed analyses to 
investigate the eﬀ ect on time trends and regional 
inequalities in cancer survival of some of the more 
speciﬁ c measures listed in the cancer plan and the 
Cancer Reform Strategy,40 such as MDTs, shorter 
waiting times for investigation and treatment, and the 
training and specialisation of surgeons and other 
specialists. Such studies will require more prompt and 
eﬃ  cient linkage of the national cancer data—and 
linkage to a wider range of health datasets—than is 
currently possible, as well as new ways of using this 
information to improve health policy.
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